Table 1

Risk ratios of neurotoxicities including all RCTs

Adverse event	Drug(s)	Risk ratio	95% CI	P value	Studies included	I² %
Depression	Dolutegravir	1.1	0.88 to 1.38	0.39	10	0
	Dolutegravir/rilpivirine	2.82	1.12 to 7.10	0.03	1	N/A
	Rilpivirine	1.08	0.8 to 1.48	0.6	4	33
	Combined	1.13	0.94 to 1.36	0.19	15	13
Anxiety	Dolutegravir	0.94	0.74 to 1.20	0.61	9	1
	Dolutegravir/rilpivirine	1.37	0.56 to 3.38	0.49	1	N/A
	Rilpivirine	0.68	0.35 to 1.34	0.27	3	75
	Combined	0.88	0.69 to 1.13	0.32	13	34
Insomnia	Dolutegravir	1.18	0.93 to 1.48	0.17	12	24
	Dolutegravir/rilpivirine	1.69	0.78 to 3.65	0.18	1	N/A
	Rilpivirine	1	0.71 to 1.41	1	4	62
	Combined	1.12	1 to 1.41	0.24	17	39
Dizziness	Dolutegravir	0.57	0.43 to 0.69	<0.00001	9	83
	Dolutegravir/rilpivirine	20.92	1.23 to 356.03	0.04	1	N/A
	Rilpivirine	0.35	0.28 to 0.43	<0.00001	5	0
	Combined	0.47	0.41 to 0.53	<0.00001	15	79
Suicidal behaviour	Dolutegravir	0.93	0.56 to 1.57	0.8	11	0
	Dolutegravir/rilpivirine	2.99	0.31 to 28.63	0.34	1	N/A
	Rilpivirine	1.32	0.36 to 4.8	0.67	3	17
	Combined	1.02	0.64 to 1.62	0.93	15	0

N/A, not applicable; RCTs, randomised controlled trials.